Author
Listed:
- Yi-Zhou Jiang
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
- Ke-Da Yu
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
- Wen-Ting Peng
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
- Gen-Hong Di
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
- Jiong Wu
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
- Guang-Yu Liu
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
- Zhi-Ming Shao
(Shanghai Medical College, Fudan University
Shanghai Medical College, Fudan University)
Abstract
Among chemotherapeutic agents, paclitaxel has shown great efficacy against breast cancer. Prediction of paclitaxel response may improve patient outcomes. Here we show, using exome sequencing, that in comparison with pre-treatment biopsies, two TEKT4 germline variations are enriched in post-treatment tumours. We find TEKT4 variations in ~\n10% of an independent cohort of 84 pairs of samples. Tektin4 (encoded by TEKT4) associates closely with tubulin in doublet microtubules and helps stabilize these structures. These two TEKT4 germline variations in a high cis linkage are biologically relevant, as the ectopic expression of variant TEKT4 deregulates the microtubule stability, antagonizes the paclitaxel-induced stabilizing effect of microtubules and increases paclitaxel resistance. Furthermore, TEKT4 germline variations are associated with reduced disease-free survival and overall survival compared with wild-type TEKT4 in patients undergoing paclitaxel-based chemotherapy. Taken together, we reveal a potential mechanism of resistance to paclitaxel through the acquisition of germline variations in breast cancer.
Suggested Citation
Yi-Zhou Jiang & Ke-Da Yu & Wen-Ting Peng & Gen-Hong Di & Jiong Wu & Guang-Yu Liu & Zhi-Ming Shao, 2014.
"Enriched variations in TEKT4 and breast cancer resistance to paclitaxel,"
Nature Communications, Nature, vol. 5(1), pages 1-12, September.
Handle:
RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms4802
DOI: 10.1038/ncomms4802
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms4802. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.